MedPath

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

🇷🇺Russia
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

50

Active:5
Completed:8

Trial Phases

6 Phases

Early Phase 1:1
Phase 1:4
Phase 2:16
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (40 trials with phase data)• Click on a phase to view related trials

Phase 2
16 (40.0%)
Not Applicable
9 (22.5%)
Phase 3
9 (22.5%)
Phase 1
4 (10.0%)
Early Phase 1
1 (2.5%)
Phase 4
1 (2.5%)

Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis

Phase 2
Recruiting
Conditions
Biphenotypic Acute Leukemia
Acute Lymphoblastic Leukemia
Myeloblastic Leukemia
Bilinear Leukemia
Malignant Lymphoma, Non-Hodgkin
Myelodysplastic Syndrome
First Posted Date
2025-01-01
Last Posted Date
2025-01-01
Lead Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Target Recruit Count
50
Registration Number
NCT06756152
Locations
🇷🇺

National medical research center of pediatric haematology, oncology and immulogy named after Dmytriy Rogachyov, Moscow, Russian Federation

Emapalumab Efficacy in Children With Primary Hemophagocytic Lymphohistiocytosis

Active, not recruiting
Conditions
Primary Hemophagocytic Lymphohistiocytosis
First Posted Date
2024-09-19
Last Posted Date
2024-10-01
Lead Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Target Recruit Count
7
Registration Number
NCT06587191
Locations
🇷🇺

Research Institute of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis

Phase 2
Active, not recruiting
Conditions
Acute Myeloid Leukemia
Biphenotypic Acute Leukemia
Myelodysplastic Syndromes
Acute Lymphoblastic Leukemia
Malignant Lymphoma
Interventions
First Posted Date
2024-06-26
Last Posted Date
2024-08-23
Lead Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Target Recruit Count
150
Registration Number
NCT06475820
Locations
🇷🇺

Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology, Moscow, Samory-Mashela,1, Russian Federation

Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors Stratification

Recruiting
Conditions
Ganglioneuroma
Neuroblastoma
Ganglioneuroblastoma
First Posted Date
2024-03-06
Last Posted Date
2024-05-20
Lead Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Target Recruit Count
200
Registration Number
NCT06296732
Locations
🇷🇺

Research Institute of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity

Phase 2
Recruiting
Conditions
Inborn Errors of Immunity
Interventions
First Posted Date
2024-01-10
Last Posted Date
2024-01-10
Lead Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Target Recruit Count
100
Registration Number
NCT06199427
Locations
🇷🇺

HSCT department, Moscow, Russian Federation

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 10
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.